Benedikte Hasselbalch
About
In The Last Decade
Benedikte Hasselbalch
17 papers receiving 477 citations
Peers
Comparison fields: 5 of 50
- Genetics 399
- Molecular Biology 156
- Cancer Research 151
- Pulmonary and Respiratory Medicine 136
- Oncology 90
Countries citing papers authored by Benedikte Hasselbalch
This map shows the geographic impact of Benedikte Hasselbalch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benedikte Hasselbalch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benedikte Hasselbalch more than expected).
Fields of papers citing papers by Benedikte Hasselbalch
This network shows the impact of papers produced by Benedikte Hasselbalch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benedikte Hasselbalch. The network helps show where Benedikte Hasselbalch may publish in the future.
Co-authorship network of co-authors of Benedikte Hasselbalch
This figure shows the co-authorship network connecting the top 25 collaborators of Benedikte Hasselbalch. A scholar is included among the top collaborators of Benedikte Hasselbalch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benedikte Hasselbalch. Benedikte Hasselbalch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 6 | |
| 6 | 3 | |
| 7 | 2 | |
| 8 | 1 | |
| 9 | 8 | |
| 10 | 9 | |
| 11 | 1 | |
| 12 | 17 | |
| 13 | 2 | |
| 14 | Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. | 71 |
| 15 | 32 | |
| 16 | 42 | |
| 17 | 19 | |
| 18 | 184 | |
| 19 | 84 | |
| 20 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.